By Katherine Hamilton
Masimo forecast a stronger than expected 2025 as it refocuses on its core medical business.
In its fourth-quarter earnings report, the medical technology maker guided for adjusted earnings per share of $5.10 to $5.40 in 2025, ahead of the $4.69 a share analysts polled by FactSet were expecting. It expects healthcare revenue to be $1.50 million to $1.53 million this year, which would be an 8% to 11% increase.
Masimo posted a fourth-quarter loss of $349.6 million, or $6.52 a share, in the three months ended Dec. 28, compared with a profit of $34 million, or 63 cents a share, a year earlier.
Stripping out certain one-time items, adjusted per-share earnings were $1.80, ahead of the $1.43 forecast by analysts, according to FactSet.
Revenue rose 9%, to $600.7 million. Analysts surveyed by FactSet forecast revenue of $593 million.
Masimo is currently undergoing a strategic realignment to focus on its core healthcare business. In January, the Irvine, Calif., company named Katie Szyman, who was head of patient monitoring at Becton Dickinson and Co., as its new chief executive.
"As a result of our strategic realignment efforts in the fourth quarter, we expect to see increased earnings and cash flow in 2025 and beyond," Szyman said.
Operating expenses more than doubled compared with the previous year, contributing to the overall loss.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 25, 2025 16:45 ET (21:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。